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Greater public awareness and early screening has led to patients 
presenting with smaller breast tumours. 
Knowledge about axillary node metastases is essential to accurately stage 
early breast carcinoma and plays an important role in determining 
prognosis and post-operative management. 
The standard method of evaluating the axilla has been a complete axillary 
lymph node dissection. This can result in significant patient morbidity, . 
particularly lymphoedema and neurological disturbances in the ipsilateral 
arm. 
Sentinel lymph node (SLN) biopsy is being used increasingly for staging 
early breast carcinoma in place of complete axillary lymph node dissection. 
The optimal method to identify the SLN and has not been clearly elucidated 
in the literature. 
A number of techniques have been proposed for identifying SLN/s. The 
main debate centres on whether to use a blue dye or radiopharmaceutical 
method either singly or in combination. The different injection techniques 
described in the literature reliably identify the "true" SLN/s in the axilla. It 
can thus be hypothesised that predefined SLNs representative of the entire 
breast, can be found irrespective of the injection site of the 
radiopharmaceutical or blue dye. 
With any new technique some degree of learning is required in order to 
perform it accurately in a reproducible manner with a minimum failure rate 
Xl 
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and complications. To validate the new technique, a study consisting of the 
removal of the SLN together with a complete axillary lymph node clearance 
is required. This allows the nuclear medicine physician and the surgeon to 
determine the pathological status of the identified sentinel lymph node and 
the rest of the axillary lymph nodes in order to assess the false-negative 
rate of the sentinel lymph node. 
AIM 
To determine if the single intratumoral technique with preoperative 
Iymphoscintigraphy is a valid and reliable method to identify the SLN/s. 
PATIENTS AND METHODS 
Patients with a clinical stage 1(1-2 cm) or a stage II (>2cm - 5 cm) breast 
carcinoma and non-palpable axillary lymph nodes were included. 
The technique for SLN identification consisted of: 
1. A single intratumoral injection of 99m Tc-nanocolloid. 
2. Preoperative Iymphoscintigraphy. 
3. Intraoperative removal of the SLN guided by the handheld gamma 
probe and methylene blue dye within 36 hours. 
The first 36 procedures included a SLN biopsy followed by complete 
axillary lymph node clearance. The SLN/s together with the remaining 
axillary lymph nodes was sent for histological analysis. This was done to 
assess the accuracy of the intratumoral injection technique in identifying 




Based on the experience gained and the high identification rate of the true 
SLN from the first 36 procedures, the subsequent surgical management of 
the axilla changed as a complete axillary lymph node clearance was done 
only if the SLN was positive at frozen section. 
RESULTS 
A total of 102 patients were analysed and 103 SLN procedures were 
performed as one patient had bilateral synchronous breast carcinoma. The 
median age of the patients was 52 yrs (range 30-77 yr). 
The first 36 procedures had a SLN identification rate of 89% as only in 32 
procedures was the SLN identified. There was a false-negative rate of 5%) 
in 28 SLN biopsies when compared to 28 complete axillary lymph node 
clearances. 
The overall SLN identification rate was 960/0 (991103). Ninety percent of the 
SLNs were visualised within two hours by Iymphoscintigraphy. 
In 97% (96199) of the procedures, the SLN was located in the axilla 
irrespective of the location of the tumour while in 30/0 (3199), it was noted 
only in the internal mammary node (IMN) chain. The axilla was the only site 
in 73196 (760/0) procedures while in 23 it occurred in the axilla as well as 
other sites. Of these 12123 were in the 1M N chain, 10123 were in the 
intramammary area and in 1123 the SLNs were seen in the IMN and 
intramammary sites. 
CONCLUSION 
A single intratumoral injection technique with preoperative 




Breast carcinoma is a worldwide problem with over one million new cases 
diagnosed each year1. In South Africa it is the second commonest 
carcinoma in women2. 
Greater public awareness and early screening has led to patients 
presenting with smaller breast tumours. Knowledge about axillary node 
metastases is essential to accurately stage early breast carcinoma and 
plays an important role in determining prognosis and post-operative 
management. The incidence of axillary nodal involvement in early breast 
carcinoma ranges between 20 - 40%. Clinical examination is a poor 
determinant of nodal involvement and histological examination is thus 
essential to identify the latter3. 
The standard method of evaluating the axilla has been a complete axillary 
lymph node dissection. This can result in significant patient morbidity, 
particularly lymphoedema and neurological disturbances in the ipsilateral 
arm3. Sentinel lymph node (SLN) biopsy has revolutionised the 
investigation and management of axillary nodes. Identification and 
meticulous histological examination of the sentinel lymph nodes allows for 
accurate prediction of the tumour status of the regional axillary basin and 
avoids the morbidity and expense of complete axillary dissection in node 
negative patients4,5,6. 
A number of techniques have been proposed as the optimal method for 
identifying SLN/s. The main debate centres on whether to use a blue dye 
or radiopharmaceutical method either singly or in combination. 
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The different injection techniques described in the literature all reliably 
identify the "true" SLN/s in the axilla. It can thus be hypothesised that 
predefined SLNs representative of the entire breast, can be found, 
irrespective of the injection site of the radiopharmaceutical or blue dye7,B. 
When a new technique is introduced in a unit, some degree of learning is 
required in order to perform it accurately in a reproducible manner with a 
minimum failure rate and complications. To validate the new technique, a 
study consisting of the removal of the SLN together with a complete axillary 
lymph node clearance is required. This allows the nuclear medicine 
physician and the surgeon to see whether the pathological status of the 
sentinel lymph node identified, correctly reflects the status of the rest of the 
axillary lymph nodes in order to assess the false-negative rate. 
According to the American Society of Breast Surgeons, a validation study 
of at least 30 or more cases should be done in order to attain a SLN 
identification rate of 850/0 and a false-negative rate of less than or equal to 
5%9,10,11, 
SLN biopsy in breast carcinoma was studied at Groote Schuur Hospital in 
1995-1996. Disappointing results with the blue dye method alone led to the 
technique being abandoned 12. In April 2000, Amersham International (UK) 
donated an intraoperative handheld gamma probe to the Nuclear Medicine 
Department. To initiate the use of Iymphoscintigraphy and SLN biopsy, 
Amersham International (UK) brought out Professor C.A. Hoefnagel, a 
nuclear medicine physician, and Dr E.J. Th. Rutgers, a surgical oncologist, 




At the Netherlands Cancer Institute13, this technique was initiated in breast 
carcinoma shortly after Morton originally described lymphatic mapping in 
melanoma. They felt it was best to inject the radiopharmaceutical directly 
into the primary tumour so that the radiopharmaceutical would follow 
exactly the same route as the disseminating tumour cells. A concern was 
that the injection of the radiopharmaceutical distant to the tumour might 
increase the risk of crossing a lymphatic watershed and thus visualise a 
node that was not the true sentinel lymph node 13. Therefore, in order to 
preserve the normal physiology of lymph drainage, a small volume of only 
0.2 ml was injected into the tumour13. 
Criticism of the intratumoral injection technique centres on the belief that 
injection into a tumour causes tumour cells to spread along the needle 
track with the release of additional tumour cells into the circulation. 
However, surgeons and pathologists routinely perform fine needle 
aspiration cytology or tru-cut needle biopsy to confirm the diagnosis of 
breast carcinoma with no apparent adverse events 14. 
The average breast tumour is present for 5-10 years before it is clinically 
detected. During this period tumour cells continuously detach from the 
primary tumour. The rate of tumour cell shedding has been measured in 
breast carcinomas of rats and was found to be 3.2 million cells per 24 
hours per gram of tissue 13. Tumour cells that are shed from a solid tumour 
as a result of manipulation are transient and therefore unlikely to have a 
measurable impact on the prognosis 13. 
The intratumoral injection of the radiopharmaceutical reliably migrates to 
regional lymph node basins. This was confirmed in studies done at the 
Netherlands Cancer Institute where in 516/531 (970/0) patients, a SLN was 
identified 13. The advantages of thetechnique are that more than 950/0 of the 
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injected radioactivity remains at the injection site and on average only 
0.16% of the injected dose ends up in the SLN. The small volume injected 
will also easily be removed by a lumpectomy 13. 
It is against this background that we designed the present study to identify 
the SLN. The radiopharmaceutical was injected intratumorally, followed by 
preoperative Iymphoscintigraphy aided by the handheld gamma probe and 
blue dye intraoperatively. 
-4-
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To determine if the single intratumoral technique with preoperative 






In 'On the Glands', one of history's earliest known medical texts; 
Hippocrates described, "white blood in nodes". Aristotle noted fibres 
containing colourless fluid located between blood vessels and nodes 15. In 
1627, Gasparo Aselli 15 first recognised the lymphatic system. In the mid 
1600, Swammerdam 15, first discovered the presence of valves in the 
collecting lymphatic channels. By the early nineteenth century, the anatomy 
of the lymphatic system was almost completely characterised. However, 
the embryological origin is still controversial i.e., whether the lymphatic 
channels arise from veins or de novo from Iymphangioblasts or both 15. 
The lymphatics function as a draining system by regulating tissue fluid 
haemostasis by returning macromolecules (proteins) to the blood 
circulation. Via this route about 25-50% of the total circulating plasma 
protein enters the blood circulation per day. It also serves as a major route 
for dissemination of tumour cells, the transport of bacteria and immune 
cells to distant sites on entering the bloodstream 15. 
ORGANISATION OF THE LYMPHATIC SYSTEM 
There are 5 main categories in the lymphatic system: the capillaries, 
collecting channels, lymph nodes, trunks and ducts. Their sizes range from 
1 O~m to 2mm in diameter. Lymph is formed when interstitial fluid is 
absorbed into blind ending lymphatic capillaries (initial lymphatics), which 
are 1 0-60 ~m in diameter and are significantly larger than arteriovenous 
capillaries (8~m). Initial lymphatics consist of a single layer of endothelial 
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cells with a discontinuous basement membrane that overlaps and serves 
as valves, which are approximately 1 0-25nm wide. This membrane is 
attached to the surrounding tissues by means of anchoring collagen 
filaments that prevent the collapse of the lymphatic capillaries. The 
basement membrane mainly consists of type IV collagen and does not 
contain heparin sulphate, proteoglycan or fibronectin that is found in 
vascular capillary membrane. The osmotic pressure gradient and 
fluctuating intraluminal pressures caused by contraction and the forward 
flow of lymph at the interstitial lymphatic interface, explain the filling of 
lymphatic capillaries 15,16. 
Following lymph formation, lymph drains from the lymphatic capillaries to 
the collecting lymphatics. These have mainly bicuspid valves but may be 
unicuspid or tricuspid with smooth muscles in their walls. This is unlike the 
lymphatic capillaries, which are devoid of valves and smooth muscles 15,16. 
Segments of collecting lymphatics between valves are called 
Iymphangions, which serve as contractile components contracting in a 
peristaltic fashion propelling the lymph into the next component at regular 
intervals to prevent backflow of lymph. This is also aided by systemic 
forces such as respiration, blood pressure and skeletal muscle 
movement 15,16. Lymph flow and lymphatic contractility increases in 
response to tissue oedema (oedema safety factor), warm baths, exposure 
to cold (ice packs) and intermittent external pressure. Sustained external 
pressure however, reduces lymph flow. All collecting channels pass 
through lymph nodes, which are capsular and organised in clusters 




The lymphatic trunks are the largest channels that drain lymph from the 
final set of lymph nodes into ducts with the exception of lymphatics from 
the intestinal, hepatic and lumbar areas that drain directly into a sac-like 
structure; the distal end of the thoracic duct (cisterna chyli), which lies on 
the 1 st and 2nd lumbar vertebrae between the aorta and the right crus of the 
diaphragm. The thoracic duct opens near the union of the internal jugular 
and subclavian veins and is responsible for draining most of the body, 
while the right lymphatic duct, which enters the right brachiocephalic vein, 
drains mostly the right upper quadrant of the body17. 
The normal lymph flow is 2-4 litres per day at rest and varies according to a 
diurnal rhythm and physiological needs. It normally contains clotting 
factors, protein, water insoluble fats and lymphocytes. The protein 
composition of lymph is equivalent to interstitial fluid, which in turn is similar 
but less concentrated than that of blood plasma. However, the lymph 
protein content varies with the region from which the lymph is drained. 
Intestinal lymph has a high fat content so that the lymph is turbid and is 
often called chyle18. 
BREAST LYMPHATICS 
INTRODUCTION 
Knowledge of the lymphatic pathways from the breast is paramount to the 
understanding of the natural course, staging and the treatment of breast 
carcinoma 19. Following the introduction of sentinel lymph node biopsy in 
early breast carcinoma there has been a renewed interest in the anatomy 
and physiology of the lymphatics of the breast2°. Currently, different 
injection sites, timing of scintigraphic imaging and surgery are based on 
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theories relating to the structure of lymphatic channels, particle uptake into 
lymphatic channels and lymph flow20. 
HISTORICAL BACKGROUND 
The anatomy of breast lymphatics has been studied for several centuries. 
At the end of the eighteenth century, Cruikshank and Mascagni20 
independently described 2 main lymphatic draining routes i.e. the external 
and internal system. The external route drains the skin, nipple and 
lactiferous ducts to the axilla. The internal route draining the dorsal part of 
the breast was thought to perforate the pectoral and intercostal muscles. 
Within the intercostal spaces these lymphatics were noted to join the 
plexus from the liver and the diaphragm and follow the internal mammary 
channels on either side. In 1770 Campher2o, a Dutch physician was the first 
to identify lymphatic drainage to lymph nodes along the internal mammary 
channels. These nodes extended from the 5th intercostal space to the 
retroclavicular nodes. Vital dye studies showed that the deep lymphatics 
drained into the internal mammary nodes. These deep lymphatics arise 
from breast lobules; leave the dorsal surface of the breast by piercing the 
pectoral and the intercostal muscles to reach the internal mammary 
chain20. In 1830, Sappey20 using mercury injections into lymphatic channels 
concluded that most of the breast tissue drains centripetally into the 
subareolar plexus and then to the axilla. Rouviere2o and Grant & 
Associates2o later confirmed these findings. At the end of the 19th and the 
beginning of the 20th century, anatomists refuted this concept and stated 
that additional lymphatic routes existed. In the 1950's, Turner-Warwick21, 
injected colloidal gold C98Au), with a particle size of 5nm, into the breast 
and concluded that more than 750/0 of the breast drains to the ipsilateral 
axillary lymph nodes. The remainder drains into the ipsilateral internal 
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mammary chain from both the medial and lateral quadrants of the breast21. 
Hultborn et al22 and Vendrell-Torne et al23 and Uren et al24 confirmed this. 
Less common drainage routes are lymphatics passing through so-called 
interval nodes, the interpectoral and intramammary nodes, on the way to 
the axilla and internal mammary chain. The interpectoral (Rotter's) 
node 19,25 is found between the pectoralis major and minor muscle. The 
intramammary nodes are situated in the breast parenchyma2o. 
Occasionally drainage from the breast goes directly to supraclavicular 
nodes, as well as sporadic drainage to the contralateral internal mammary 
chain, which occurs if ipsilateral lymph drainage is impaired by tumour 
growth, previous surgery or radiotherapy. Blockage of normal lymph flow 
can also cause retrograde drainage to the liver via the internal mammary 
chain. Drainage to posterior intercostal lymph nodes and anterior 
intercostal nodes has also been described20. 
DISTRIBUTION OF BREAST LYMPHATICS 
It is generally accepted that drainage from the breast can occur to lymph 
nodes at a number of different sites. Both the axilla and the internal 
mammary chain receive lymph from all quadrants of the breast. 
The breast receives its blood supply from 3 main vessels - mainly the 
axillary and internal mammary vessels with a minor contribution from the 
lateral perforating branches of the intercostal vessels. The lymphatic 
drainage in these 3 directions is approximately proportional to the blood 
supply so that more than 750/0 of the total lymph drains to the axilla and the 





Subcla",an ~mph lrunk - ___ 
Apical nodes ___ ---,. 
Lymphatic channel --=-=~ 
Cenlral 
nodes -~-:::--------4:;~ 
Lymphatic drainage of the breast, anterior view. (From Agur AMR, Lee MJ, Grant's 
Atlas of Anatomy. 10th Edition, Philadelphia, Lippincott Williams & Wilkins 1999.) 
LYMPH NODES 
INTRODUCTION 
Lymphocytes and monocytes not only circulate in blood and lymph but also 
accumulate in discrete organised masses forming the Iymphoreticular 
system. The main components of this system include lymph nodes, 
thymus, spleen, tonsils, adenoids and Peyer's patches with less 
accumulation occurring in the bone marrow, lungs and GI tract. Lymph 
nodes are the most widely distributed and easily accessible component of 
the lymphoid tissue and are therefore frequently examined for diagnosis of 
Iymphoreticular disorders 16,26. Lymph nodes are discrete structures 
surrounded by a capsule, composed of connective tissues and a few 
elastic fibrils. The capsule is perforated by multiple afferent lymphatics on 
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its convex aspect that empty into a fenestrated peripheral subcapsular 
sinus. Lymph then moves through the node via the cortical and medullary 
sinuses, exiting through a single efferent lymphatic at the hilum on its 
concave aspect. Blood vessels only enter and leave the lymph node via the 
hilum (Figure 2A) . The cortex contains spherical aggregates of lymphoid 
cells forming the primary follicle representing the B - lymphocyte area. 
Between the primary follicles is the paracortex rich in T - lymphocytes. 
Deep to the cortex is the medulla containing numerous plasma cells and 
relatively few lymphocytes (Figure 28). Lymph nodes function as barriers, 
filters and reservoirs and are constantly reacting to multiple stimuli. Thus, 
enlarged lymph nodes in adults are almost never 'normal'. Drainage of 
tumour cell debris, tumour antigens or both induces change in the lymph 
nodes. Therefore, histological evaluation of an enlarged node in patients 
with carcinoma is necessary as it may be due to reactive hyperplasia or 




Normal lymph node architecture 
A. Schematic diagram of a lymph node. B. Low power view of a lymph node. (From 
Cotran RS, Kumar V, Collins T, Robbins Pathologic Basis of Disease. 6th edition, 
Philadelphia, WB Saunders Company 1999) 
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" REGIONAL AXILLARY LYMPH NODE BASIN 
The boundaries of the lymphatic drainage of the axilla are not well 
demarcated. There are considerable variations in the position of the groups 
of regional nodes. Grossman in 189619 was the 'first to define the number 
and position of axillary nodes. He found 12-36 nodes in the axilla and 
divided them into 4 groups. Rouviere's classification of axillary nodes into 6 
groups is currently used 19,25. 
1. LATERAL I AXILLARY VEIN GROUP 
Consists of 4-6 nodes situated medial or posterior to the axillary 
vein. It receives most of the lymph drainage from the upper 
extremity. 
2. EXTERNAL MAMMARY I ANTERIOR I PECTORAL GROUP 
Consists of 5-6 nodes and is located along the I owerllate raI border 
of the pectoralis minor muscle contiguous with the lateral thoracic 
vessel. It receives lymphatic drainage from the lateral aspect of 
the breast. 
3. SCAPULAR I POSTERIOR I SUBSCAPULAR GROUP 
Consists of 5-7 nodes located on the posterior wall of the axilla, 
along the lateral border of the scapula and are contiguous with the 
subscapular vessel. This group principally receives lymph from the 
lower neck, posterior trunk and posterior shoulder. 
4. CENTRAL GROUP 
Consists of 3-4 nodes imbedded in a pad of fat immediately 
posterior to the pectoralis minor muscle. The nodes in this group 
are the largest and are most easily palpated in the axilla. The 
clinical status is usually based on this group of nodes 19. This group 
receives lymph from the aforementioned groups but it can also 
receive lymph directly from the breast. 
- 13-
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5. APICAL I SUBCLAVICULAR GROUP 
Consists of 6-12 nodes located medial and superior to the upper 
or medial border of the pectoralis minor muscle. This group 
receives lymph from all the axillary nodes and unites with the 
efferent vessels from the apical group to form the subclavian 
trunk25. This trunk on the right drains directly into the subclavian 
vein or joins the right jugular trunk. On the left, it usually drains into 
the thoracic duct27. 
6. INTERPECTORAL I ROTTER'S GROUP 
First described by Grossman in 189619 and later by Rotter in 
189919. It consists of 1-4 nodes lying between the pectoralis major 
and minor muscles along the pectoral branches of the 
thoracoacromial vessels. Lymph from this group passes directly 
into the central or apical group. 
Surgeons and Pathologists often define metastatic axillary lymph node 
involvement into 3 levels in relation to the pectoralis minor muscle. This 
was described in 1955 by Berg, a pathologist19. 
Level I is lateral to the pectoralis minor muscle and includes the external 
mammary, lateral and scapular groups. Level II is behind the pectoralis 
minor muscle and it includes the central and interpectoral groups, whilst 
Level III is medial and superior to the pectoralis minor muscle and 
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(Ant.flor) Node Group 
Schematic drawing illustrating the major lymph node groups associated with lymphatic 
drainage of the breast. The Roman numerals indicate three levels or groups of lymph 
nodes that are defined by the location relative to the pectoralis minor muscle. (From 
Schwartz SI, Shires GT, Spencer FC, Oaly IN, Fischer JE, Galloway AC, Principle of 
Surgery. ih edition, New York, McGraw-Hili 1999.) 
The Internal mammary nodes (IMNs) are a pair of longitudinally linked 
chains of nodes on either side of the sternum, medial to the internal 
thoracic / mammary vessels. There are usually 4-5 nodes in total on each 






Worldwide, breast carcinoma accounts for 32% of all female carcinomas 
and is responsible for 19% of premature deaths in the 40-50 yr age 
group26. This is exceeded only by lung carcinoma25,26. Breast carcinoma is 
the second commonest female carcinoma after cervical carcinoma in 
Africa2. 
In South Africa during 1996 and 1997, breast carcinoma was the second 
leading cause of carcinoma in females. During this period, a total of 4460 
and 4789 new female breast carcinoma cases were reported. This 
constituted an average of 170/0 of all female carcinomas per year2. In 1996 
and 1997, the age adjusted rate for all females ranged between 27.8 per 
100000 and 29.0 per 100 000 respectively. From 1995 to 1997, the lifetime 
risk of developing breast carcinoma in South Africa increased from 1 in 36 
to 1 in 312. The incidence of breast carcinoma among South African Asian 
females is high and compares with those reported in England, Wales & 
USA2. The incidence in South African black females is similar to those 
reported in other African countries2. 
CLASSIFICATION 
Breast carcinomas are all derived from epithelial cells that line the terminal 
duct lobular unit. This is contrary to previous belief that ductal carcinoma 
arises from ducts and lobular carcinomas from lobules 1,26. 
Breast carcinomas are divided into non-invasive I in situ, which accounts 
for 15-300/0 of the total in the Western world. The proportion of in situ 
carcinoma detected is dependent on the number of women undergoing 
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mammographic screening and ranges from less than 50/0 in unscreened 
women to 15-300/0 in women who have been screened26. 
Invasive carcinoma accounts for 75-85% of the total. Ductal carcinoma (no 
special type) accounts for the majority of invasive carcinomas (79%)26. 
CLINICAL COURSE 
A breast carcinoma is usually detected as a solitary painless lump in the 
breast on palpation or routine mammogram26. It usually takes 100 days for 
a tumour to double in size so that there is a latent period of more than 8 yrs 
for a single neoplastic cell to grow to a 1-2cm clinically detectable mass 
(109 cells)25. During this latent period approximately one third will be noted 
to have axillary involvement. Mammographically detected invasive 
carcinomas are on average smaller than 1 cm in size and less than one fifth 
will have axillary metastases26. 
A number of factors influence the clinical course and prognosis of breast 
carcinoma such as; tumour size, histological subtype, tumour grade, the 
presence of angiogenesis, Iymphovascular invasion, oestrogen and 
progesterone receptors. The single most important prognostic factor, 




Ten-year survival rates of nodal negative, nodal positive and of patients with 
supraclavicular lymph node metastases or distant disease31• 
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THE SENTINEL LYMPH NODE (SLN) 
INTRODUCTION 
The management of breast carcinoma has evolved towards individualising 
treatment, minimising morbidity and maximising cure rates4. It is useful to 
know the lymphatic drainage pattern of a malignant tumour for staging, 
determining prognosis and optimiSing appropriate therapeutic 
management. The widespread use of early mammographic screening and 
enhanced public awareness has resulted in approximately 330/0 of patients 
presenting with smaller tumours of less than 1 cm in developed countries4. 
Smaller tumours are associated with less likelihood of axillary lymph node 
involvement. 70-80% of clinical Stage I (s 2cm) or II (> 2cm - Scm) lesions 
are found to have no histological evidence of metastatic involvemene2,33. 
Although level I and II axillary lymph node dissection has been the 
standard of care in the initial staging of early breast carcinoma, it adds no 
additional survival benefits and is associated with morbidity4,5,6,34. In 
patients with early breast carcinoma, often only a single node is found to 
contain tumour cells4. 
The SLN concept has revolutionised and individualised the surgical 
management of regional axillary nodes. The procedure accurately stages 
patients allowing for correct prediction of the tumour status in the remaining 
axillary nodes whilst avoiding the morbidity and expense associated with a 
complete axillary lymph node dissection4. SLN mapping may also detect 
drainage to extra-axillary sites not routinely evaluated during a standard 
axillary lymph node dissection35. 
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THE HISTORY OF THE SENTINEL LYMPH NODE 
The SLN concept is not new. In 1907, Jamieson and Dobson36 describe the 
spreading of neoplastic cells to the so-called primary gland. In 1960, Gould 
et al36 coined the term "sentinel node" in a patient with carcinoma of the 
parotid gland. In 1963, Oliver Cope32,37, in thyroid carcinoma, referred to 
the "delphian node" as the node that can "foretell the nature of the disease 
process" affecting a nearby organ. Roman Cabanas, in 197738, introduced 
the concept of the sentinel lymph node in the management of penile 
carcinoma. In 1992, Morton39,40 used this principle in the treatment of skin 
melanoma and using a dye-guided surgical procedure, removed the first 
stained lymph node and coined the definition of the sentinel lymph node. In 
1994, Giuliano41 used this concept in early, node negative breast 
carcinomas by locating and removing the sentinel lymph node also using a 
dye-guided surgical procedure. Krag and Alex42 localised the sentinel 
lymph node using a radiopharmaceutical and a handheld gamma probe. In 
1996, Albertini et al43 identified the sentinel lymph node using the 
combination of blue dye and radiopharmaceutical. Turner et a144,45 provided 
histological evidence for the sentinel lymph node hypothesis. In 103 
patients with breast carcinoma, cytokeratin immunohistochemical (I HC) 
staining was used in sentinel and non-sentinel lymph nodes that were 
negative on hematoxylin & eosin stain (H&E). The authors concluded that if 
the sentinel lymph node is tumour free by H&E and IHC staining, the 
probability of non-sentinel lymph node involvement is less than 0.1 % 44,45, 
THE SENTINEL LYMPH NODE CONCEPT 
The sentinel lymph node concept is based on two basic principles: 
1) The existence of an orderly and sequential pattern of lymphatic flow 
from the primary tumour by single or multiple lymphatic channels 
draining directly to the first (sentinel) lymph node/s within a particular 
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regional lymph node basin 46,47. 
The histopathological analysis of the sentinel lymph node/s must 
reflect the tumour status of the entire regional basin4B. 
2) The sentinel lymph node must function as an effective barrier and 
filter to retain the earliest metastatic tumour cells46,47. 
Underlying this hypothesis is the assumption that the SLN is identified, 
correctly located and removed and this is followed by meticulous 
pathological analysis46,49. 
THE SENTINEL LYMPH NODE DEFINITION 
FIGURE 4 
A sentinel lymph node is defined as a lymph node that receives drainage directly from 
the primary tumour. A second echelon node receives drainage from a sentinel node. A 
third echelon node receives drainage from a second echelon node, and so on. (From 
EurJ Nucl Med 1999; 26 Suppl: S11-S16.) 
The dictionary defines 'sentinel' as a guard, watchdog or protector50. 
A SLN is defined as the first lymph node to receive lymphatic drainage from 
the tumour. The identification varies depending on which technique is 
used34. When a radiopharmaceutical is used with preoperative 
Iymphoscintigraphy the first node/s seen on scintigraphy is called the SLN. 
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Depending on the number of channels emerging 'from the primary tumour, 
a single or multiple nodes will be regarded as sentinel lymph node/so 
Nodes seen after the SLNs are defined as 2nd echelon nodes. During 
surgery, the intraoperative handheld gamma probe identifies radioactive 
nodes but cannot readily distinguish between the sentinel and 2nd echelon 
lymph nodes. Some investigators regard all radioactive nodes as sentinel 
lymph nodes while others regard nodes with the highest count rate as the 
sentinel lymph nodes. Correlation between good quality 
Iymphoscintigraphy and surgical findings is frequently helpful34. 
Intraoperative blue dye similarly, cannot distinguish between the sentinel 
and 2nd echelon lymph node/so Most investigators regard all blue nodes or 
blue and radioactive nodes as sentinel lymph nodes. The various 
techniques used to define and find the sentinel lymph node, make 
comparison of studies with different protocols difficule4. 
THE AXILLA 
The management of the axilla in breast carcinoma patients has been a 
subject of intense debate and controversy32. Despite a tendency toward a 
conservative approach of primary breast carcinoma surgery, axillary lymph 
node dissection has remained an integral part of breast carcinoma 
management for more than a century. Axillary lymph node dissection 
results in effective regional control with a 1-20/0 recurrence rate and gives 
significant staging information but does not confer long-term survival 
benefie2,45,51. The extent of the axillary lymph node dissection depends on 
the level of dissection and the number of nodes removed52. A standard 
level I and II axillary lymph node dissection is commonly performed as only 
3% of patients will have involvement of level III nodes without positive 
nodes in levels I and 1152. Veronesi et a131 , based on a mathematical model 
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of 1 446 complete axillary lymph node dissections, also showed that a 
minimum of 10 level I nodes need to be examined to make sure that 90% 
of the axilla is pNo (pathologically no nodal metastases), 
INTERNAL MAMMARY NODES (IMNs) 
Nodes in the internal mammary chain are best identified by 
intraparenchymal injection of the radiopharmaceutical. The IMN is an 
important pathway of lymphatic drainage of both the medial and lateral 
aspects of the breast. However, the clinical practicality and relevance of 
IMN sentinel lymph node biopsy is a matter of controversy, as extra axillary 
nodes are not taken into consideration for the management of breast 
carcinoma unless there is locally advanced disease28, Whereas others 
believe it is clinically relevant as metastases exclusive to the IMN occur in 
5-10% of patients and have the same prognostic significance as axillary 
nodal metastases, Removal of these nodes is considered necessary to 
obtain complete and correct staging29,53,54,55, Most IMN metastases are 
located in the first and second intercostal spaces28,56, The most common 
complication of the IMN biopsy is a pneumothorax28, Preoperative 
Iymphoscintigraphy and intraoperative handheld gamma probe are the best 
method for the detection of IMNs. A major limitation of IMN SLN biopsy is 
the lack of confirmation of the true false-negative rate as a complete IMN 




By definition, intramammary nodes are completely surrounded by breast 
tissue and histologically they can be differentiated from low lying axillary 
and deep pectoral lymph nodes57. This differentiation can be particularly 
difficult on mammography57. Intramammary nodes can be found in virtually 
any quadrant of the breast58. The combined technique of preoperative 
Iymphoscintigraphy, intraoperative blue dye and handheld gamma probe 
for SLN identification has increased the detection of extra axillary nodes59. 
Extra axillary nodes are predominantly found in the IMN chain but also in 
the inter-pectoral region and within the breast parenchyma 
(intramammary). The frequency of finding intramammary lymph nodes both 
positive and negative has great variability and probably depends on the 
degree of vigilance and technique60. Intramammary nodes are present in 
28-47% of breast carcinomas and may have metastatic involvement in up 
to 9.8% of cases 57. The relevance of intramammary node metastases is 
difficult to assess due to low reported incidences. Once a positive 
intramammary node has been found, there is no consensus in the literature 
about what to do with the axilla6o. Egan and McSweeney61 address the 
issue of involved intramammary node and the effect on prognosis and 
treatment. Despite the small numbers in their study, they concluded that 
involved intramammary nodes in an otherwise pathologically node negative 
patient has a similar prognosis as patients with involved axillary nodes. If 
both intramammary and axillary nodes were involved there was no 
worsening of prognosis. Intramammary node involvement appears to have 
the same significance as metastatic axillary nodes where prognosis and 
treatment are of concern 57. 
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RADIOPHARMACEUTICALS IN SLN DETECTION 
The radiopharmaceutical must be able to rapidly flow through the lymphatic 
channels, localise and be retained in the sentinel lymph node by 
mechanical trapping or phagocytosis and must deliver as Iowa radiation 
dose as possible, The ability of the radiopharmaceutical to meet these 
criteria is dependent on the size and the number of particles that are 
administered62, Particle size of a colloid can be determined by electron 
microscopy, photon spectroscopy and ultracentrifugation. It should be 
noted that most particles are not uniformly shaped63. The number of 
injected colloidal particles influences the rate of outflow from the injection 
site and phagocytosis within the lymph nodes. The optimal particle size 
identified from animal studies for lymphatic drainage is estimated to be less 
than 100 nm62, Larger particles (500-2000 nm) remain trapped at the 
injection site and are unsatisfactory. Small particles « 4-5 nm) penetrate 
blood vessel capillary membranes and therefore do not migrate through 
lymphatic channels63, 
There is no consensus on the radiopharmaceutical of choice for 
Iymphoscintigraphy and SLN identification. Currently, the most widely used 
agents are all particulate in nature and are all retained in the lymph nodes. 
Choice of radiopharmaceutical varies internationally; in Europe; 99mTc 
nanocolloid, in Australia; 99mTc antimony trisulphide colloid and in America; 
99mTc sulphur colloid62,63. 
A. 99mTc antimony trisulphide colloid [99mTc_ATC] 
The first 99mTc radiopharmaceutical developed for Iymphoscintigraphy was 
99mTc_ATC. This colloid has a high percentage of uniformly sized particles 
(3-30 nm) that permits studies of a very high quality. The 99mTc-labelling of 
ATC has been proposed to occur on the surface of the particles with the 
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final particle size determined by the size of the antimony colloid used62,63. 
The agent was developed when Iymphoscintigraphy and the sentinel lymph 
node concept were not widely recognised. As a result, it was never 
developed worldwide and its use remains restricted to Australia and New 
Zealand. Uren et a163• used 99mTc_ATC to locate SLN in 34 patients with 
breast carcinoma. Images were acquired immediately and at 2.5 hours 
after 4 peritumoral injections of 2.5-7MBq of 99mTc_ATC were administered. 
Successful lymphatic drainage patterns were identified in all but three 
patients. Drainage to the ipsilateral axilla occurred in 85% of patients where 
a single SLN was seen in all cases. Adverse reactions to 99mTc-ATC have 
been reported63• 
99mTc albumin-based colloids 
Three types of albumin-based 99mTc colloid radiopharmaceutical agents 
have been studied viz., nanocolloid, microaggregated albumin and 
macroaggregated albumin62. 
1. 99mTc nanocolloid 
Biodistribution of nanocolloid depends on its particle size. More than 950/0 
are smaller than 80nm, less than 4% are between 80-100 nm and only 1% 
is more than 100 nm. It is licensed in Europe for Iymphoscintigraphy and 
bone marrow scintigraphy. It is available in a form of a 'shake and mix' kit 
and trades under different names such as Microlite, Ciscolloid, Sorin etc., 
depending on the manufacturer. The kit contains human albumin 
nanocolloid particles, stannous chloride, glucose, poloxamer 238, sodium 
phosphate and sodium phytate. The human serum albumin is obtained 
from donor blood, which tested negative for hepatitis B surface antigen and 
antibodies for HIV and the hepatitis C virus. During the reconstitution of 
99mT C nanocolloid it is critical to exclude oxygen from the vial to avoid the 
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formation of stannous technetium colloid, which will not bind to the 
albumin62,63. 
2. 99mTc microaggregated albumin 
It is licensed for liver and spleen scintigraphy. It has a particle size of 200-
3000 nm with 900/0 less than 1000 nm in size. This is not ideal for 
Iymphoscintigraphy although Paganelli et a162,63 have reported good results. 
3. 99mTc macroaggregated albumin [MAA] 
Its particle size ranges from 10 000 to 90 000 nm with very poor migration 
from the injection site to nodes therefore making it unsuitable for 
lymphoscintigraphy62. 
B. 99mTc sulphur colloid 
There are 2 methods to prepare 99mTc sulphur colloid. Initially, sulphur 
colloid was prepared by percolating hydrogen sulphide gas through an 
acidic pertechnetate solution. This resulted in very small particles. 
Nowadays, 99mTc sulphur colloid preparation is formed by the reaction of 
thiosulphate under acidic conditions. The acidified pertechnetate solution is 
added to thiosulphate in the presence of a stabilising agent. This can be 
gelatin, polygeline or mannitol. Essentially, all the pertechnetate is 
incorporated in the sulphur colloid. Heating the solution for 5-10 min at 
100 DC enhances colloid formation. The particle size ranges from 100-1000 
nm63. However, Iymphoscintigraphy requires a much smaller particle size. 
This is obtained by reducing the heating time of the colloid from 5-10 to 3 
minutes, as well as adding pertechnetate from a generator that has not 
been eluted for at least 72 hours, as this eluate would have a higher 
concentration of 99Tc pertechnetate62. By filtering this preparation through 
either a 0.1 or 0.2 /-lm membrane filter most of the particle size produced is 
less than 30 nm62. 
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C. 99mTc human serum albumin [HSA] 
This agent has a small particle size of 2-3 nm. It is not particulate and there 
is minimal retention of the agent within the lymph nodes62,63. 
D. OTHER AGENTS 
There are a number of other agents that have been used or are being 
developed for Iymphoscintigraphy including 197Hg sulphide colloid, 67Ga 
citrate and monoclonal antibodies labelled with 1111n, 1311 and 1251. Although 
several of these agents have been used with varying degrees of success, 
the use of 99mTc agents is more common owing to its availability and 
radionuclide properties . 
. Other 99mTc labelled radiopharmaceuticals have been evaluated as 
potentiallymphoscintigraphic agents such as hydroxyethyI starch, dextran, 
stannous phytate etc. These agents are only experimental at present62. 
TABLE 2 
Type of radiopharmaceuticals and particle size64. 
Type of radiopharmaceuticals Size range (nm) 
99mTc human serum albumin 2-3 
99mT C dextra n 2-3 
99mTc antimony trisulphide colloid 3-30 
ll:ltsAu colloid 5-30 
l:ll:lmTcfiltered sulphur colloid 15-50 
99mTc nanocolloid 5-80 
99mTc sulphur colloid 100-400 
l:ll:lmTc stannous fluoride 50-600 
l:lsmT C stannous phytate 1200-1000 
99mT C microcolloidal albumin 200-3000 
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RADIATION DOSIMETRY AND PROTECTION 
The main radiation consideration is the absorbed radiation dose to the 
patient, the cumulative radiation exposure to staff (medical, technical & 
theatre) involved with SLN biopsy and possible contamination of the 
surroundings. The radiopharmaceutical uptake in the SLN is only a small 
fraction of the administered dose. At the Netherlands cancer Institute, the 
activity in 103 SLNs was measured approximately 23.5 hours after 74 MBq 
of 99mTc-nanocolioid was injected intratumorally in 51 patients with breast 
carcinoma. The mean uptake in the SLNs was 6.5 kBq (range 0.03-102 
kBq), which is 0.16% (range 0.001-2.50/0) of the injected 
radiopharmaceutical64. These measurements reflect spontaneous 
lymphatic drainage i.e., without any massaging of the injection site. Bass et 
al64 showed that massaging of the injection site improved the blue staining 
of SLNs but the radiopharmaceutical uptake was not significantly affected. 
The greatest absorbed radiation dose is by far at the injection site i.e., the 
local skin, the primary tumour or peritumoral bed, assuming that most of 
the radiopharmaceutical will remain there for total decay. In the case of the 
intraparenchymal (intratumoral or peritumoral) or subdermal injections 
above the tumour, the injection site will be of least concern, as it will be 
routinely resected. Radiation dose to the lymph nodes was calculated to be 
in the order of 47mGy64. The radiation exposure to the total body, bone 
marrow or ovaries is insignificant and roughly ten times less than that of a 





Effective dose of Radiological and Nuclear medicine procedures65. 
i 
INVESTIGATi"ON EFFECTIVE DOSE (mSv) 
SLN study 0.32 
99mTc bone scan 3 
99mTc perfusion lung scan 1 
l~JI thyroid scan 4 
i 
99mT C scintimammography 11 
Chest X-ray 0.02 i 
Mammography 0.4 
Plain Abdominal X-ray 1 
! Lumbar spine X-ray 1.3 
Intravenous urography 2.5 
Barium meal 3 
Brain CT 2.3 
Abdominal CT 10 
Chest CT 8 
Waddington et a165, measuring radiation doses to patient and surgical staff 
during surgery at 24hr after a subdermal injection of ~9mTc colloidal 
albumin, found the effective dose to the patient to be 0.32 mSv, which is 
comparable to mammography. The whole body dose to surgical staff was 
less than 2mSv i.e., less than 0.2% of the annual dose limit. Surgical 
swabs may contain up to 100/0 of the injected dose64,65. The exposure to the 
pathologist from the breast histological specimen (activity <3.7 kBq) and 
the SLN (activity <0.2 kBq) is low. Persijn64 also concluded that the 
radiation exposure to patient and personnel is low and he extrapolated that 
a surgeon operating 3-6 hrs after injection of 75 MBq can perform at least 
2000 SLN biopsies per year before reaching the annual dose limit to the 
hands as the general public (50mSv/yr). 
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At the Netherlands Cancer Institute, Hoefnagel et al64 calculated the 
radiation exposure and dose to those personnel closely involved in SLN 
biopsy. At the time of injection the nuclear medicine physician, injecting a 
radiation dose of 80MBq of 99mTc colloid with an unshielded syringe held 
between the fingers for approximately 2 minutes, will receive the highest 
dose i.e. 2.45 mSv to the hands and 0.06 mSv to the body. During the 
dynamic phase (up to 30 minutes), the nuclear medicine technologist 
standing more than 2 metres away will receive 0.23 mSv. At delayed 4 hr 
imaging, the nuclear medicine technologist will receive 0.145 mSv. The 
nuclear medicine physician marking the sentinel lymph node at 4 hrs or 
later, will receive a dose to the hands of 19.2 mSv. During surgery between 
4 and 24 hrs, the surgeon will receive 115 mSv to the hands and 1.16 mSv 
to the body assuming that the procedure takes one hour and the 
radioactive specimen is handled with surgical instruments most of the time. 
During surgery after 24 hrs, the same procedure can be carried out with a 
ten times lower radiation dose to the surgeon's hands (11.5 mSv) and body 
(0.11 mSv). During pathological assessment of the tumour, assuming that 
this is done after fixation and only takes 30 minutes, the remaining activity 
will only be 0.0195 MBq so that the radiation dose to the pathologist is 
negligible i.e., 0.0225 mSv to the hands and 0.0002 mSv to the body. The 
total radiation exposure to the nuclear medicine technologist at 2 metres 
including attendance at surgery is 0.42 - 0.68 mSv depending on the time 
of surgery64. An additional radiation exposure to the patient and nuclear 
medicine technologist is from the Cobalt-57 or Technetium-99m flood 
source, which is used as a transmission source during imaging to outline 
the body contour. The radiation dose from the Cobalt-57 or Technetium-
99m flood source of equal activity (370 MBq), is 70IJSv to the patient66,67. 
There is an additional radiation dose of 52.51JSv to the nuclear medicine 
technologist from the preparation of the Technetium-99m flood source66. 
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IN"IECTION TECHNIQUES TO IDENTIFY THE SLN 
The injection technique is important as the success of the SLN biopsy is 
determined by its identification rate and false negative rate. 
The SLN identification rate is defined by the percentage of procedures in 
which the SLNs have been successfully localised and removed68. 
The false-negative rate is the frequency of the SLN being pathologically 
negative while other axillary lymph nodes harbour metastases9,68. 
Several radiopharmaceutical injection sites for the identification of the SLN 
have been documented. These include the peritumoral, intratumoral, 
subdermal or intradermal above the tumour, subareolar or periareolar with 
radiopharmaceutical volumes ranging from 0.2 to 16 mls20 and doses from 
37-370 MBq36. 
Variables such as the injection site, volume and dose have their 
advantages and disadvantages. Those who use a small volume prefer not 
to disturb the normal physiology of lymph flow and avoid the risk of 
visual ising non-sentinel lymph nodes. Those who use a large volume seek 
to alter the normal physiology, thereby increasing the chance of visualising 
a lymph node34• Surprisingly, the different injection sites reliably identify the 
"true" SLN in the axilla7,8. 
From the above it can be hypothesised that predefined SLNs 
representative of the entire breast can be localised irrespective of the site 
of the radiopharmaceutical or vital dye injection8. The functional lymphatic 
anatomical basis for this hypothesis revolves around the breast lymph flow 
concept proposed by Grant et al in 19538 and Halsell et al in 19638. They 
showed, using the vital dye staining and radiography that all lymphatic 
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channels of the skin and the underlying breast parenchyma communicated 
with the subareolar lymph complexes8. In 2000, Borgstein et al also stated 
that the breast functions as a single biological unit with preferential lymph 
drainage pathways from all quadrants draining essentially towards the 
same axillary SLN69. 
SUBAREOLAR AND PERIAREOLAR TECHNIQUES 
ADVANTAGES 
1. It is easy to teach (minimal training), practical, reliable and 
reproducible8,7o,71,72. 
2. It is away from the axilla and primary tumour. This allows detection 
of the sentinel lymph node that is in close proximity to the tumour 
by avoiding the shine-through effect from the injection site8,70,71,72. 
3. It avoids the theoretical possibility of seeding tumour cells along 
the needle track8,7o,71,72. 
4. It avoids the difficulties relating to the size of the tumour, non-
palpable tumours, sonographically ill-defined tumours and 
previous manipulation of the primary tumour73. 
5. It requires a small radiopharmaceutical dose and volume with less 
radiation exposure to patient and hospital staff36. 
6. It allows rapid visualisation of SLN8,70, 71, 72, 
DISADVANTAGES 
1. Non-visualisation of internal mammary lymph nodes74,75, 
2. The visualised node may not be the first node that drains the 






1. Allows visualisation of extra-axillary lymph nodes 74. 
2. Depicts the drainage pattern from the tumour to the visualised 
lymph node/s74. 
DISADVANTAGES 
1. The blossoming effect from multiple deposits around the tumour 
may obscure visualisation of intramammary lymph nodes and 
axillary lymph nodes situated in close proximity to the injection 
site. This can lead to incorrect identification of the SLN74. 
2. May increase the variability of results due to the different 
lymphatic drainage patterns from the 4 quadrants of the breasf4. 
3. Less frequent visualisation of lymphatic channels leading to a 
SLN74. 
4. Delayed visualisation of SLN in patients with large breasts and 
those who are postmenopausal74. 




1. When inserting the needle into the tumour, the resistance of the 
tumour is felt, this leads to a more accurate and focal deposition 
of the tracer ensuring the precise mapping of the actual drainage 
pattern of the primary tumour13,74. 
2. On average, a mere 0.160/0 of the injected dose ends in the SLN 
while 950/0 of the dose remains at the injection site13,74. 




1. Theoretically, tumour cells can spread along the needle track36,46. 
2. Immediate leakage of the tracer can occur from tumour into the 
peritumoral space due to the relatively high interstitial and 
intercellular pressures36,46. 
3. The tumour may intrinsically be devoid of organised lymphatic 
channels resulting in poor and slow drainage36,46. 
4. Lymph nodes closely situated to the tumour are obscured during 
imaging by the scatter or blossoming effect from the activity at the 
injection site36,46. 
5. Visualisation of the SLN is variable and can be detected early or 
late36,46. 
SUBDERMAL OR INTRADERMAL TECHNIQUE 
Due to the embryological origin in the ectoderm, the lymphatic drainage 
from the skin overlying the breast is richer than the drainage from a 
tumour3. 
ADVANTAGES 
1. Allows visualisation of lymphatic channels and early detection of 
the SLN within 15-30 minutes post injection3. 
2. Allows the use of a smaller dose and vOlume3. 
3. Less blossoming effect and radiation exposure3. 
4. Easy to perform3. 
DISADVANTAGE 





The use of radio pharmaceuticals enables preoperative visualisation of the 
SLN. Preoperative scintigraphy consists of a dynamic phase followed by 
delayed static images. 
THE PURPOSE OF DYNAMIC IMAGING 
1. To determine the number of nodes in the same or a different regional 
drainage basin that is on a direct drainage pathway from the primary 
tumour76. 
2. To differentiate the true sentinel lymph node from second echelon 
nodes76. 
3. To determine the exact location of the sentinel lymph node/s thereby 
minimizing the extent of surgical dissection76. 
4. To enable easier identification of the true sentinel lymph node/s on 
delayed static images76. 
5. To identify drainage to extra-axillary nodes76. 
Preoperative Iymphoscintigraphy increases the likelihood of finding all true 
sentinel lymph nodes1o,4B,77,7B,79,Bo. The nuclear medicine physician provides 
the "road map" to guide the surgeon34. 
THE PURPOSE OF STATIC IMAGING 
Early images [30min - 2hr) 
1. Where there is non-visualisation of SLN on dynamic imaging76,B1. 
2. To confirm the radiopharmaceutical activity seen on the dynamic 
images and to distinguish activity in a lymphatic channel from 
nodal activity76,B1. 
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3. To identify additional uptake in echelon nodesB1. 
4. To ensure accurate counting statistics of SLN counts with the 
handheld gamma probe. 
Late images [4 - 24hr] 
1. Where there is non-visualisation of SLN on dynamic and early 
static imagesB1. 
2. Where there is poor visualisation of SLN on dynamic and early 
static imagesB1 . 
CAUSES OF NON-VISUALISATION OF SLN 
1. Significant tumour infiltrationBo. 
2. Age of patient (~ 50 yrs) due toB2,B3: 
a. Decrease in tissue turgor with resultant decrease in the intra-
lymphatic hydrostatic pressure that drives the tracer into the 
node; 
b. Nodal tissue is replaced by fat, decreasing the phagocytic 
activity of reticuloendothelial cells in the lymph node thereby 
reducing the ability to concentrate the tracer even if it is 
delivered successfully. However, this is disputed by Hughes et 
al84 and Derossis et a1B5. 
3. Increase in tumour grade may cause non-visualisationBo,B6. 
CAUSE FOR DELAYED VISUALISATION OF SLN 
Haigh et alB7 found that the tracer transit time is slower in women with large 
breasts than those with small breasts. 
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THE HANDHELD GAMMA PROBE 
The first use of the handheld gamma probe in a surgical procedure was in 
1949 by Selverstone et alBB where it was used to define an astrocytoma 
using a Geiger MOiler counter after IV injection of 32p, a beta emitter. 
During the subsequent years various probe designs were developed but 
there was minimal clinical application for its use. Since 1990 the usefulness 
of the handheld gamma probe has significantly increased with the 
acceptance of the SLN concept in melanoma and breast carcinomasBB. 
The use of the handheld gamma probe preoperatively helps the surgeon to 
locate the precise position of the underlying sentinel lymph node before an 
incision is made. Intraoperatively, it guides the surgeon with an auditory 
signal to the SLN and to the possible presence of residual lymph nodes. 
Intraoperative mapping without preoperative Iymphoscintigraphy may not 
be optimum as the first (SLN) node may be indistinguishable from other hot 
nodes detected by the handheld gamma probe. Furthermore, the detection 
of drainage to unexpected drainage basins is difficult to determine with the 
handheld gamma probe alone, unless preoperative Iymphoscintigraphy has 
been done7B• Radioactive counts are measured in the regional lymphatic 
drainage basin using the handheld gamma probe before, during and after 
the SLN has been excised 7B• Once the SLN is excised, the maximum count 
rate (ex vivo) in counts per second (cps), of the excised tissue is 
ascertained and recorded. The ex vivo count rate is usually 2-3 times 
higher than the in vivo count rate as there is no attenuation of the excised 
tissue to reduce the count rate. A background reading is made of the SLN 
bed to ensure that the entire SLN is removed. To ensure that there are no 
residual radioactive nodes, a background reading of less than 10 cps is 
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usually acceptable78,88. The SLN should at least contain ten times the count 
of the background78. 
The handheld gamma probe consists of a detector, collimator, digital or 
analog display with an audio-signal detector and power supplies. At 
present, commercially available handheld gamma probes have either a 
Sodium iodide [Nal] or Cesium iodide [Csl] scintillation crystal or Cadmium 
Zinc Tellerium [CdZnTe] or CdZn semi-conductor detectors88,89. 
The scintillation detector based handheld gamma probes, using a Nal or 
Csi crystal, connected to a photomultiplier tube by a fibre optic cable have 
the advantages of reliability, relative low cost and high sensitivity especially 
for medium to high-energy photons. However, the disadvantages include 
poor energy resolution, poor scatter rejection and bulkiness89. 
The C-Trak handheld gamma probe consists of a Csi crystal mounted in a 
tip of stainless steel tube, which is angled for better manoeuvrability. The 
crystal is inside a tungsten collimator so that it is shielded from external 
radiation striking the side of the tube. 
Semi-conductor probes are compact, have excellent energy resolution and 
good scatter rejection. Their main disadvantage is lower sensitivity. 
Intraoperative handheld gamma probes for sentinel lymph node detection 
require excellent spatial resolution to allow precise localisation of the small 
target (SLN)89. 
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VITAL BLUE DYES IN SLN LOCALISATION 
The various dyes used as potential lymphatic mapping agents include 
methylene blue, isosulfan blue (Iymphazurin 1 %) and patent blue V7B. 
Methylene blue, due to its smaller molecular weight (319.9) and the lack of 
sulphonic acid groups in its structure, does not bind to plasma proteins. It 
will, therefore, rapidly diffuse into the surrounding tissues either with 
minimal or no staining of the SLN90,91. In contrast, patent blue V and 
isosulfan blue with large molecular weights enter the lymphatics and are 
retained in the lymph nodes with minimal diffusion into the surrounding 
tissue91 . 
However, Simmons et al92 and Blessing et al91 reported that methylene 
blue dye has a similar localisation rate to isosulfan blue. Methylene blue 
dye is used at many institutions to localise the SLN in breast carcinomas 
because of its greater availability, lower cost and decreased risk of adverse 
side effects when compared to isosulfan blue92. In a few cases, the use of 
isosulfan blue has resulted in serious anaphylactic reaction 91,93. 
Stradling et al92 however, reported that 5 patients developed skin lesions 
(variety of forms) secondary to only the intradermal injection of methylene 
blue dye. None of these lesions required debridement or other 
interventions as all responded to topical creams92. 
The blue dye is injected through a needle at the time of surgery at various 
sites (peritumoral, intratumoral, subdermal I intradermal above the tumour, 
subareolar I periareolar) using .a volume ranging from 0.5 to 3mls. The 
breast is gently massaged to move the blue dye along the lymphatic 
channels. The interval between dye injection and skin incision depends on 
the location of the primary breast tumour and varies from 5 to 10 minutes 7B. 
By using the blue dye technique alone, one cannot distinguish between the 




drainage sites or the location of the SLN so that the surgical incisions tend, 
to be larger. The combination of using blue dye with a radiopharmaceutic91 
is more reliable as it provides a visual guide and an auditory signal during I 
I 
SLN dissection. . 
The literature reviewed by Hoefnagel et al64 revealed that the combined 
use of Iymphoscintigraphy, the handheld gamma probe and blue dye 
yielded the best results with a detection rate varying from 93-1000/0, blue 
dye only 66-820/0 and the handheld gamma probe only 84-930/0. According 
I 
to Nieweg et al77, the detection rate for Iymphoscintigraphy, handheld 
I 
gamma probe and blue dye was 93.80/0, blue dye only 76.30/0, handheld ; 
gamma probe only 91.5%, Iymphoscintigraphy and handheld gamma probe 
87.8%, blue dye and handheld gamma probe 91.30/0. According to Kraft et' 
a194, the detection rate for Iymphoscintigraphy, handheld gamma probe and 
blue dye was 98.4%, blue dye only 74.4% and handheld gamma probe 
only, 88.70/0. The false-negative detection rate was the lowest with the 
combined technique varying between 1-5% compared to 11-130/0 with only 
i 
the handheld gamma probe and 11-170/0 with only the blue dye64. 
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THE ROLE OF PATHOLOGY 
It is of critical importance that the node examined is truly the sentinel lymph 
node. Currently, to determine that the node removed is the SLN depends 
on the information from preoperative Iymphoscintigraphic identification by 
the nuclear medicine physician and the intraoperative localisation by the 
surgeon using the handheld gamma probe and blue dye. The ability to 
detect metastatic tumour in the axillary lymph node is directly related to the 
extent of the axillary lymph node dissection, the methods used for 
histopathological analysis and the experience of the pathologist9s. 
Traditional staging of the ipsilateral axilla included a complete axillary 
lymph node dissection and a single random H&E staining for 
histopathological analysis. Unfortunately, 300/0 of the patients who were 
considered to have negative nodes developed recurrent disease. Not 
surprisingly as serial sectioning and immunohistochemical (IHC) staining 
could detect occult metastases in as many as 250/0 of "negative" axillary 
lymph nodes. These findings suggested that either the tissue being 
sampled or the means of disease detection was inadequate96. 
SERIAL SECTIONING 
In 1948, Saphir and Amromin97 first suggested that a standard pathological 
examination consisting of bisecting the node and examining each side with 
H&E stain was inadequate for the consistent detection of axillary lymph 
node metastases. They hypothesised that the examination of serial 
sections taken systematically through the entire lymph node would 
increase the detection rate of metastatic deposits compared with the 
examination of a single random section stained with H&E. While no 
standard definition of serial sectioning exists, a variety of protocols have 
demonstrated that evaluating a lymph node with serial sections increases 
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the metastatic tumour detection rate from 7 to 330/0 when compared to a 
single H&E section. Routine serial section on all lymph nodes from a 
complete axillary lymph node dissection is cost prohibitive, labour intensive 
and time consuming 97. 
In a report from the Ludwig breast cancer study group, lymph nodes taken 
from 921 patients were sectioned at 6 levels after a negative H&E stain of a 
single section. The examination of the serial sections identified occult 
metastatic disease in 83 (9%) patients. At 6 years, both the disease free 
survival rate (DFS) 53% vs. 71 %, and the overall survival rate (OS) 70% 
vs. 86%, were worse in those patients with occult micrometastatic disease 
when compared to those without occult disease97. 
De Mascarel et al97 examined nodes from 785 patients with an average of 
three H&E sections per node, also showed that the 10 year DFS and OS 
rates were worse for those patients with micrometastases compared to 
those without micrometastatic disease97. 
IMMUNOHISTOCHEMICAL STAINING 
IHC staining of axillary nodes against the epithelial membrane antigen, 
mucin or cytokeratin antibodies has been shown to enhance the tumour 
detection rate. However, pathologists must be aware that lymph nodes may 
contain benign epithelial inclusions or cytokeratin immuno-reactive 
mesenchymal cells. Many retrospective studies have shown an increased 
tumour detection rate of 10-150/0 when IHC staining is added to routine 
H&E evaluation of axillary nodes44,97. 
De Mascarel et al97 stained a single level of each tumour-free lymph node 
with a cocktail of monoclonal antibodies against epithelial cell antigens. 
With this technique they were able to detect micrometastases in 41% of 
previously node negative invasive lobular carcinoma patients and 100/0 of 
previously node negative ductal carcinoma patients97. 
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McGuckin et a197, detected micrometastases in 25% of specimens 
examined by performing both serial sectioning and IHC staining on axillary 
nodes that were negative on routine H&E staining. 
REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION 
(RT-PCR) 
RT -PCR is even more sensitive than immunohistochemistry in detecting 
metastatic tumour. It is able to detect approximately one cancer cell per 107 
normal cells compared to one per 105 for IHC and one per 104 normal cells 
in routine histologically examination. Ironically, the marked sensitivity of 
conventional PCR has hindered its clinical application since the currently 
defined breast tumour associated markers are detectable in normal tissue. 
It is not able to quantitatively distinguish tracer amounts of gene expression 
in normal tissue from excessive amounts in metastatic tissue. However, 
real time RT -PCR technology can quantify gene expression from 
metastatic tissue. The assay allows for the simultaneous analysis of 
multiple genes and is highly automated, rapid and reproducible96. 
CLINICAL SIGNIFICANCE OF MICROMETASTASES 
In the new TNM classification98; 
• A micrometastasis is defined to be between 0.2 and 2 mm in its 
greatest diameter. 
• A tumour deposit less than 0.2 mm is referred to as an isolated 
tumour cell and to be recorded as pNo. 
• A tumour deposit in a lymph node drainage area with no evidence of 
lymph node architecture is considered a lymph node metastasis if its 
contour is smooth; and if irregular, it will fall in the p T category 
(irregular margin of the primary tumour) or it may be due to venous 
invasion. 
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Detecting a nodal micrometastasis (:s; 2 mm) is related to its size, position 
(subcapsular marginal sinus or parenchyma) 99, However, its clinical 
relevance is controversial because not all micrometastases will progress 
and grow to form distant tumours 100, A definite survival disadvantage is 
associated with occult nodal metastases but the size at which they become 
significant is undefined. In the era of lymphatic mapping and SLN biopsy, 
the detection of micrometastases is enhanced by focusing the pathologist's 
efforts on one or two dissected SLNs compared to the analysis of all nodes 
in a complete axillary dissection which is costly, labour intensive and time 
consuming, With the trend towards early mammographic diagnosis of 
smaller tumours, a method to optimise detection of micrometastasis with 
the aim of maximising tumour detection while at the same time, minimising 
labour and costs will become more important in the future97, 
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RELIABILITY OF INTRAOPERATIVE SLN ANALYSES 
INTRAOPERATIVE FROZEN SECTION 
There is still some debate about the optimal intraoperative pathological 
evaluation of the SLN. This is a crucial issue since the primary aim of SLN 
biopsy is to stage the patient's axilla reliably so that axillary dissection 
together with the removal of a primary tumour and SLN can be performed 
as a one-stage operation 101. It must be realised that during a regular frozen 
section 25-50% of the tissue is lost. This may lead to missing some SLN 
tissue with micrometastases. It is difficult to estimate the chance of this 
occurring, since this depends on the size and distribution of 
micrometastases 102, 103. 
The sensitivity of frozen section analysis of SLN, ranges from 56.7-100% 
and depends largely on the technique applied, the experience of the 
pathologist, the histological type and size of the tumour. This point was 
clearly illustrated by the Van Diest's 101 group who reported significant 
variation in the sensitivity between 56.7 and 87% depending on the 
experience of the pathologist. Metastatic diseases in patients with larger 
tumours metastasise more readily and are easily identified on frozen 
section than metastases from a smaller primary tumour. In an intensive 
study involving 890 patients, nodal metastases were diagnosed on frozen 
section in only 6 of 143 patients with stage la tumours as opposed to 45 of 
119 patients with Stage II tumours. Metastatic lobular cells may not be 
much bigger than the native lymph node cells making interpretation 
difficule01 . The delay of 20 minutes caused by frozen section analysis is 
acceptable since during this delay the primary tumour can be excised 102. 
This allows the surgeon to perform immediate axillary lymph node 
dissection when the SLN is positive on frozen section. In case of a negative 
SLN frozen section, the final paraffin section result will ultimately determine 
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whether axillary lymph node dissection will be performed at a later stage. 
This occurs in less than 10% of patients as verified by Van Diest et al 102 
and Giuliano et a1 104. 
An alternative to frozen section is intraoperative touch imprint cytology. 
The sensitivity ranges from 93-100% 105 with no false positives and a false-
negative rate of 4.9%. The false-negative rate is associated with metastatic 
lobular carcinoma as it is more difficult to identify and to interpret. The 
false-negative rate is also associated with the difficulty in identifying 
micrometastases 105. 
TABLE 4 
The advantage of touch imprint cytology versus frozen section 103, 105. 
Touch imprint cytology Frozen section 
Rapid « 1 Omin) => less anaesthetic & 
Time consuming (30m in) 
operative time 
Inexpensive More expensive 
Preserve tissue allowing further investigations 
25-50% of tissue loss 
if required . 
Highly specific Less specific 
No artefacts Freeze-thaw artefacts 
Easy to perform multiple sections Serial sectioning - time consuming 
I HC has shown to decrease false-negative rates of imprint cytology or 
frozen section by upstaging 10-20% SLN negative to SLN positive 
patients106. Although the most accurate way to detect micrometastases 
intraoperatively remains unknown, there are still concerns about the 
impl ication of false-negative results and the clinical relevance of 
micrometastases detected only by IHC and reverse polymerase chain 
reaction . With improved technology the ability to detect smaller metastases 
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is becoming a reality. However, our understanding at present of its 
biological relevance is still lacking. 
SIGNIFICANCE OF NON-SENTINEL LYMPH NODES 
The true benefit of lymphatic mapping and SLN biopsy is that an accurate 
histopathological status of the axilla can be determined without the patient 
incurring the costs and morbidity associated with complete axillary lymph 
node dissection. However, for patients with a tumour positive SLN, the true 
extent of axillary involvement is not known until a complete axillary lymph 
node dissection is performed. 50% of patients with a tumour positive SLN 
will have no metastatic tumour detected in the remaining axillary nodes 
after axillary lymph node dissection. Several groups have searched for 
potential predictors of non-sentinel lymph node metastases in patients with 
a positive SLN metastasis97. They found that 4 factors have a possible 
significant association with non-sentinel lymph node metastases namely97; 
• The size of the primary tumour, 
• The peritumoral Iymphovascular invasion, 
• The size of the SLN metastasis and; 
• The extracapsular extension of the SLN metastasis. 
Failure to accurately identify and evaluate the true SLN could lead to 
incorrect staging and inadequate treatment that may lead to regional 
recurrences. This may adversely impact on patient prognosis, as the 




REASONS FOR FALSE-NEGATIVE SLN BIOPSY 
• Learning curve and surgical experience. 
This is the single most important factor for determining success for 
SLN biopsy, which is dependant on correct patient selection and 
adherence to protocol and technique 107, 10B. 
• Prior excisional biopsy 109. 
• Age of 50 or more years 109. 
• Obesity due to fatty replacement of breast tissue leading to poor 
lymphatic flowB4 . 
• Clinically undetected involved axillary nodes. It has been 
hypothesised if there are more than 5 positive nodes, the 
lymphatics progressively become obstructed with malignant cells 
and the injected radiopharmaceutical and blue dye are redirected 
via collaterals to false-negative SLNs 109. 
Leidenius et al 110 disputed the fact that removal of more than 5 
lymph nodes does not decrease the false-negative rate. 
• The method used for histopathological analysis 111, 112. 
- 49-
PATIENTS AND METHODS 
PATIENTS AND METHODS 
The study was devised as a prospective evaluation of sentinel lymph node 
mapping and biopsy for early breast carcinoma. It was initiated in April 
2000 and was completed in January 2004 in patients attending our surgical 
outpatient breast clinic. 
PATIENT CRITERIA 
The selection criteria were based on the recommendations in the literature. 
I NCLUSIONS3,32,45: 
• Clinical stage I (1-2cm) or stage II (> 2cm - Scm). 
• Non-palpable axillary lymph nodes. 
EXCLUSIONS 109,113: 
• Tumour size more than Scm (Stage III and above), 
• Palpable axillary lymph nodes, 
• Previous surgery or radiotherapy to the axilla , 
• Previous excisional biopsy of the primary tumour 
• Previous neoadjuvant chemotherapy, 
• Pregnancy or lactating, 
• Multifocall multicentric tumour. 
STUDY PROTOCOL 
The technique to identify the SLN included preoperative 
Iymphoscintigraphy after a single intratumoral injection of 
99mTc nanocolloid . This was followed by the intraoperative removal of the 
SLN, guided by the handheld gamma probe and methylene blue dye. 
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The first 36 procedures included a SLN biopsy followed by complete 
axillary lymph node clearance. The SLN/s together with the remaining 
axillary lymph nodes was sent for histological analysis. 
This was done in order to assess the accuracy of the intratumoral injection 
technique in identifying the true SLN and to predict the status of the rest of 
the axillary lymph nodes. 
Based on the experience gained and the high identification rate of the true 
SLN in the first 36 procedures, the subsequent surgical management of the 
axilla changed as a complete axillary lymph node clearance was done only 
if the SLN was positive at frozen section. 
ETHICAL AND LEGAL CONSIDERATIONS 
The Research Ethics Committee of the University of Cape Town approved 
the study protocol and informed consent was obtained from all patients by 
the surgeon. 
PROCEDURE AND TECHNIQUE 
Lymphoscintigraphy was performed on all patients the day before surgery 
in the Nuclear Medicine Department. 
INJECTION TECHNIQUE 
The patients were injected with 99mTc-nanocolioid (Nanocoll, Manufacturer: 
GIPHARMA S.r.1. Saluggia (Vercelli), Italy. Marketing Authorized Holder: 
Amersham Health). The 99mTc-nanocolloid was prepared according to the 
manufacturer's instruction in a concentration of 500MBq per ml. The 
activity in a volume of 0.2 ml was drawn up with a 1 ml syringe attached to a 
26 gauge needle. 0.1 ml of air was then drawn into the syringe. The syringe 
was inverted so that the air was placed behind the activity to ensure 
complete delivery of the radiopharmaceutical. 
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Prior to the single intratumoral injection, the breast tumour area was 
covered with a sterile drape with an opening to allow access to the injection 
site. The drape served to prevent possible droplet contamination from the 
needle tip on removal of the syringe after the injection (Figure 5). The 
remaining activity in the syringe was measured to calculate the actual 
administered dose to the patient. 
FIGURE 5 
Demonstration of the injection technique. 
IMAGING PROTOCOL 
DYNAMIC PHASE 
We used a large field of view single head gamma camera (General Electric 
Starcam 400 AC - Horsholm, Denmark) fitted with a low energy high-
resolution collimator. The patient was in a supine position with the arm 
above the head. The detector was placed in a lateral projection to the 
patient, on the ipsilateral side to the tumour. This was done to obtain the 
best view of the axilla. A cobalt-57 flood source was supported in an 
upright position in a grooved perspex holder placed on a chair adjacent to 
the patient on the contralateral side. The cobalt flood source was used as a 
transmission source to outline the body contour. Dynamic images were 
then acquired at 20 seconds per frame in a 64X64 matrix for 20 minutes 
(Figure 6). 
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FIGURE 6 
Patient positioned between the detector head and the transmission source for dynamic 
and lateral static acquisitions. 
STATIC PHASE 
Static images were acquired for 300 seconds in a 256X256 matrix at 30 
min, 2hr and 4hrs post injection in the lateral and anterior projections, with 
the cobalt flood source placed in the contralateral and posterior positions 
respectively. For the anterior projection, the cobalt flood source was placed 
below the patient on a footstool. 
The lateral projections were obtained with the patient in the same position 
as for the dynamic phase. The anterior projections were acquired with the 
patient supine and the arm on the affected side abducted to 90 degrees to 
the body in a similar position, as it would be in theatre. 
At 4hrs, an additional anterior oblique view (35 degrees) of the affected 
side was acquired for 3 minutes without the cobalt flood source. This image 
sought to provide more accurate localisation of the SLN and to identify 
possible nodal clusters (Figure 7). Additional delayed static images as 
described above were acquired between 6 to 24 hrs after the injection in 
patients where the SLN was poorly visible or not seen at 4hrs. 
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FIGURE 7 
SKIN MARKINGS 




SLN in a 
cl uster => 
<=lnJection 
sIte 
R L AT 4HR 
Oblique image showing SLN in a cluster. 
External skin markings using a permanent marker pen were done at 4hrs 
with the patient's arm abducted to the same degree, as it would be in 
theatre. The initial markings corresponded to the nodal uptake seen on the 
camera images. However, the final skin markings were done using the 
handheld gamma probe (C-trak: Care Wise, Morgan Hill, CA, USA) (Figure 
8) and corresponded to the area of the highest probe reading as the 
camera skin marking overlying a node is subject to variation depending on 
the angulation of the parallel hole collimator, patient size and the position of 
the arm 114. 
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FIGURE 8 
C-trak handheld gamma probe 
PROCESSED DATA 
The images were displayed and recorded on a single emulsion film using a 
GE Starimager (Figure 9). The dynamic study was grouped into 4 frames at 
300 sec/frame. One imaging film, which was used for a single procedure, 
was divided into 4 quadrants. The first quadrant of the film contained the 4 
grouped images of the dynamic study while the remaining quadrants 
displayed the static images that were taken at the various time intervals. A 
copy was made for the surgeon who performed the SLN biopsy. 
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The SLN was identified as being the first lymph node seen at the end of the 
afferent lymphatic channel that emerged from the injection site or, if no 
afferent channels were seen, the first lymph node/s appearing in each 
regional draining basin74. 
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A. Single channel with a single SLN in left axilla. 
ANT 30min 
B. Two SLNs seen in left axilla simultaneously without channels. 
RLAT 4HR ANT 4HR 
c. 
C. Single SLN in the IMN without a channel. 
A senior nuclear medicine consultant and I viewed and reported all 
scintiscans at the same time. 
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SURGERY 
Surgery was performed within 36 hrs of the radiopharmaceutical injection. 
Under general anaesthesia, 0.5-1 ml of methylene blue dye was injected 
intratumorally immediately prior to draping the patient for surgery. The 
identification and excision of the SLN was the first part of the procedure 
followed by the planned breast surgery. Before an incision was made, the 
surgeon used the handheld gamma probe to confirm the location of the 
SLN as seen on Iymphoscintigraphy. Sound-directed probing and digital 
display readings were then used to locate the radioactive SLN node/s, 
which mayor may not have stained blue. According to the surgical 
protocol, the node was defined as sentinel if the nodal counts were 10X 
background or visually stained blue. An ex vivo or bench count in counts 
per second (cps) was taken from the excised SLN/s followed by an in vivo 
background count from the site of the excised node/s to confirm removal of 




PATIENT AND TUMOUR CHARACTERISTICS 
A total of 102 patients were analysed and 103 SLN procedures were 
performed as one patient had bilateral synchronous breast carcinoma. The 
median age of the patients was 52 yrs (range 30-77 yr). 
57/103 (550/0) breast tumours were clinically Stage I while 46/103 (450/0) 
were clinically Stage II. 51/103 (49.50/0) of the breast tumours were located 
in the right breast and 52/103 (50.50/0) were located in the left breast with 
the upper outer quadrants predominating (Figure 11 ). 
FIGURE 11 
Primary tumour distribution in various quadrants. 
At surgery, 36 breast tumours had a wide local excision (WLE) and 67 had 
a mastectomy. 
The histological tumour types in the 103 breasts were: 
• Ductal 94/103 (91%); 
• Lobular 7/103 (70/0); 
• Papillary 1/103 (10/0); 




Patient and tumour characteristics 
CHARACTERISTICS n = 103 
Age (yrs) 
Median 52 
, Range 30-77 
Clinical Tumour Stage 
TI 57 {55%} 
Til 46 (45%) 
Tumour Type 
Ductal 94 (91%) 
Lobular 7 (7%) 
Papillary 1 (1%) 
Medullary 1 {1%} 
Surgery 
WLE 36 (35%) 
Mastectomy 67 (65%) 
L YMPHOSCINTIGRAPHY 
All breast tumours received a single intratumoral injection of 99n'lTc_ 
Nanocolloid with a median dose of 89 MBq (range: 65 -104MBq) in ,a 
volume of 0.2 mL 
Standard imaging up to 4 hours was performed in 101/103 (98%)) 
procedures; of these, 8/101 (8%) procedures had additional delayed 
images varying from 6 to 24 hrs due to poor or non-visualisation of the SLN 
. at the end of 4hrs. Due to technical reasons, 2/103 (2%) procedures were 
not imaged according to standard protocol and were terminated at two 
hours. However, a SLN was visualised at that time. 
LYMPHATIC CHANNELS 
These were seen in 68/103 (66%)) procedures. 
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SENTINEL LYMPH NODES 
NUMBER OF SLN SEEN 
The first 36 procedures had a SLN identification rate of 890/0 as a SLN was 
identified in only 32 procedures. Four procedures showed no SLN on 
Iymphoscintigraphy. The overall preoperative Iymphoscintigraphy 
identification rate was 96% as the SLN was seen in 99/103 procedures. In 
the remaining 4, despite delayed images up to 24hrs, no SLN was seen. A 
single SLN was seen in 68/99 (69%) procedures, 2 SLN's were seen in 
22/99 (22%) procedures, 3 SLNs were seen in 7/99 (7%) and 4 SLN's were 
seen in 2/99 (2%) procedures. 
TABLE 6 
Number of nodes seen at preoperative Iymphoscintigraphy 






TIMES SLN FIRST SEEN 
In the 99 successful procedures a total of 141 SLNs were seen. 
In 28/141 (200/0) the SLNs were first seen on the dynamic phase, 19/141 
(130/0) at 30 minutes, 80/141 (570/0) at 2 hours, 13/141 (90/0) at 4 hours and 
1/141 (1%) were seen at 6 hours. 
127/141 (90%) SLNs were seen by two hours. 
- 61 
RESULTS 
SITES OF SLN 
Of the 141 SLNs, 114 (81%) were located in the axilla, 11 (8%) 
intramammary and 16 (110/0) were in the IMN chain. 
In 96/99 (97%) procedures irrespective of the location of the tumour the 
axilla was the commonest site, while in 3/99 (3% ) the SLN was found only 
in the IMN. The axilla was the only site in 73/96 (76%) procedures, while in 
23 the SLN was seen in the axilla as well as other sites. Of these 12/23 
were in the IMN chain, 10/23 were in the intramammary area and in 1/23 
the SLNs were seen in the IMN and intramammary sites. 
SECOND ECHELON NODES 
Second echelon nodes were seen in 53/99 (540/0) procedures. The axilla 
was the commonest site in 49/53 (920/0). In 11/49 (22%) in addition to the 
axilla, they were also seen in the IMN and intramammary areas. In 4/53 
(8% ) of the procedures, no second echelons were seen in the axilla but 
were seen in the IMN and intramammary areas. 
SURGICAL AND HISTOLOGICAL FINDINGS 
Of the 'first 36 procedures that were used to validate the study, only 29 
(810/0) had a SLN biopsy and a complete axillary lymph node dissection. A 
total of 64 SLNs were removed compared to 42 SLNs seen on 
Iymphoscintigraphy due to some SLNs occurring in clusters. 
In the remaining 7(19% ) who had complete axillary lymph node clearances, 
a SLN was not removed, as 4 were not seen on preoperative 
Iymphoscintigraphy, 1 was in the internal mammary chain whilst 2 were 
very poorly seen on Iymphoscintigraphy in the axilla and the surgeon was 
unable to detect and remove the SLN node. 
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A total of 450 axillary nodes were harvested in only 35 procedures, as the 
axillary specimen of one patient was lost in transit to the pathologist. 
Thus in the final histological analysis only 28 SLN biopsies were compared 
to 28 complete axillary lymph node clearances. 
There was metastatic involvement in 10/28 (36%) SLN biopsies. Complete 
axillary lymph node clearance in this group revealed that in 4 the SLN was 
the only positive node while in the remaining 6 other axillary nodes had 
metastatic involvement. 
There was no metastatic involvement in 18/28 (64%) SLN biopsies. 
Complete axillary lymph node clearance in this group revealed 17 who had 
no metastatic involvement, while 1 had metastatic involvement in the 
remaining axillary lymph nodes. 
TABLE 7 
Histological findings of SLN versus the remaining axillary nodes. 
REMAINING AXILLARY 
SLN NODES 
I POS NIEG 
POS 10 6 4 
NEG 18 1 17 
The false-negative rate was 1/18 (5%) and the sensitivity of the SLN biopsy 
was 10/11 (91%), specificity 17/17 (100%) with a negative predictive value 
of 17/18 (94.4%) and a positive predictive value 10/10 (100%). There was 
concordance between the SLN and remaining axillary nodes in 23/28 
(82% ). 
In the remaining 67 procedures 19 had complete axillary lymph node 
clearances. Of these, 14 had a positive SLN at frozen section, in 2 the SLN 
was in the IMN while in 3, the SLN biopsies were cancelled . In 48 
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procedures the SLN was negative and no axillary lymph node clearances 
were done. 
Of the 14 who had a positive SLN intraoperatively, the SLN was the only 





Lymphatic mapping and SLN biopsy is rapidly replacing complete axillary 
lymph node dissection in the staging of the axilla in early breast carcinoma 
due to its lower morbidity, but it is not yet universally accepted46. Currently, 
there is no consensus on the optimal method for defining and identifying 
the SLN 115, 116, 
The main issues pertaining to SLN biopsy are the following: 
• What is the optimal technique? 
• Does it accurately predict axillary lymph node status? 
• Does the SLN technique actually decrease axillary morbidity? 
• Does a false-negative SLN have an adverse effect on patient 
management and outcome? 
A number of techniques have been proposed as the optimal method for 
identifying SLN/s. The main debate centres on whether to use a blue dye 
or radiopharmaceutical method either singly or in combination. 
Some prominent authors support using only the blue dye method 
(GLliliano)46 while others recommend only the radiopharmaceutical method 
. (Veronesi)46. 
Literature reviews by Hoefnagel et a164, Nieweg et al77 and studies by Kraft 
et a194, Cody et al 117 and d'Eredita et al118 reported that the best results for 
localising the SLN are obtained with the combination of 
Iymphoscintigraphy, a handheld gamma probe and blue dye. 
In this study we evaluated whether the single intratumoral injection 
technique is a reliable and valid method to identify SLN/s. In the first 36 
- 65-
DISCUSSION 
procedures we assessed the accuracy and false-negative rates of 
lymphatic mapping using this technique. 
Currently, there is no consensus on the radiopharmaceutical of choice for 
Iymphoscintigraphy and SLN identification, its injection volume, activity, site 
and imaging protocol after injection46, 114, 119. In this study, we used 99mTc_ 
nanocolloid with a median dose of 89 MBq in a volume of 0.2 mls. 
The analysis of the first 36 procedures showed a SLN identification rate of 
890/0 and a false-negative rate of 5%. The results of which influenced the 
subsequent management of patients with early breast carcinoma as only 
those at surgery with a positive SLN at frozen section, continued to have a 
complete axillary lymph node clearance. 
The overall SLN identification rate was found to be 96% (99/103) with 900/0 
visualised by two hours. The present study therefore supports other 
authors who reported increasing success in SLN identification as they 
gained experience4. 
At the Netherlands Cancer Institute13 using the single intratumoral injection 
technique the sentinel lymph node identification rate was 97% as the SLN 
was identified in 516/531 patients. 
In Giuliano's original study115, 120, he used a peritumoral injection of blue 
dye, with a SLN biopsy success rate of 660/0, with 960/0 accuracy. 
Subsequent studies by the same group and others using the blue dye 
alone have reported success rates from 71 % to 94% and accuracy 
between 970/0 and 1000/0. Krag et a1 115,120 used the peritumoral injection of 
radiopharmaceutical to achieve a SLN biopsy success rate of 820/0 with 
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100% accuracy. Albertini et a1 115, 120 achieved a success rate of 92% with 
100% accuracy using a combination of blue dye and radiopharmaceutical 
in a series of 62 patients. Veronesi and colleagues 115,120 used the 
subdermal injection of radiopharmaceutical in 163 patients and achieved a 
SLN biopsy success rate of 98% with 98% accuracy. 
Kern 121, 122, using subareolar injection of blue dye alone, achieved a 
success rate of 98% with an accuracy of 100%. 
Embryologically, the breast develops from the ectoderm. Its network of 
lymphatics communicates with the subdermal plexus and drains 
predominantly into the ipsilateral axillary nodes7, 115. Borgstein et a17,115 
demonstrated 1000/0 concordance in localising the sentinel lymph node 
using an intradermal injection of blue dye and a peritumoral injection of 
radiopharmaceutical. This high rate of concordance not only supported the 
theory that the intraparenchymallymphatics drain into the same nodal 
basin as the lymphatics of the overlying skin; it showed that the two regions 
drain to the same sentinel lymph node. Linehan et al 123 who reported a 
950/0 concordance between intradermal radiopharmaceutical injection and 
peritumoral injection of blue dye provided additional evidence for this 
theory. Klimberg et al 124 found a 95% concordance with the subareolar 
injection of radiopharmaceutical and peritumoral blue dye. Pelosi et al72 
found a 92% concordance with a subdermal injection of 
radiopharmaceutical and the periareolar injection of blue dye. These 
studies all suggest that, regardless of tumour location within the breast, all 
lymphatics drain to the same sentinel lymph node7,115. 
The different injection techniques described in the literature all seem to 
reliably identify the "true" SLN/s in the axilla. It can thus be hypothesised 
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that predefined SLNs representative of the entire breast, can be found 
irrespective of the injection site of the radiopharmaceutical or blue dye7,8. 
Lymphoscintigraphy is used as a "road map" and increases one's level of 
confidence in identifying the SLN at the end of a lymphatic channel. This 
facilitates differentiation of a SLN from a 2nd echelon node. Using the 
intratumoral injection technique, lymphatic channels were observed in 
68/103 (660/0) of our procedures. 
Lymphoscintigraphy also allows visualisation of the number of SLNs in the 
regional drainage basin and may facilitate the skin incision needed for their 
removal. Without the benefit of imaging, the surgeon has to remove all 
radioactive nodes, as it may be impossible to distinguish between the SLN 
and echelon nodes. In this study preoperative Iymphoscintigraphy showed 
SLNs in 99/103 (96%» procedures of which 31/99 (31%) had more than 
one SLN. Second echelon nodes were seen in 53/59 (54%) of the 
procedures. 
Drainage to the axilla predominated irrespective of the site of the primary 
tumour125, 126, 127. This pattern was observed in this study as 96/99 (97%) 
drained to the axilla. 
The final skin markings of the SLN were based on the handheld gamma 
probe as the patient's size and arm positioning influenced the gamma 
camera image. 
The pattern of lymphatic drainage in anyone patient to non-axillary nodes 
is unpredictable and difficult to determine from the location of the primary 
tumour4. According to Nieweg et al13 and Uren et a1 128, non-axillary nodes 
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are present in up to 27% and 35% of patients respectively. They are 
usually seen with the intratumoral and peritumoral injections and not with 
the subdermal 1 intradermal and periareolar 1 subareolar injection 
techniques 129,130. Our study demonstrated lymph nodes in the breast tissue 
(intramammary) in 11/99 (11 %) and in the IMN in 16/99 (16%) of the 
procedures. 
Poor visualisation of the SLN at the end of 4hrs necessitated additional 
delayed imaging between 6 and 24 hrs in 4/103 (4%) procedures, 1 had 
extensive tumour infiltration of the lymph nodes and 3 had no direct 
relationship to tumour presence in the nodes as all the axillary nodes 
removed were free of tumour. 
Non-visualisation of SLNs occurred in 4/103 (4%) procedures; 
• 2 had extensive metastatic lymph node infiltration. 
• 2 had no obvious reasons. 
Failure to accurately identify and evaluate the true SLN could lead to 
incorrect staging and inadequate treatment, and lead to late regional 
recurrences. This may adversely impact on patient prognosis9. 
There was a single false-negative SLN in the first 36 procedures. There 
was no obvious explanation for this finding. 
Limitations of the study: 
The first 36 procedures included a SLN biopsy followed by a complete 
axillary lymph node clearance to assess the accuracy of the intratumoral 
injection technique in identifying the true SLN and to predict the status of 
the rest of the axillary lymph nodes. 
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In the subsequent 67 procedures 14 had a SLN biopsy followed by a 
complete axillary lymph node clearance, as the SLN was positive at frozen 
section. I n the remaining 53 procedures we were unable to determine 
whether the SLN identified at Iymphoscintigraphy truly reflected the status 
of the remaining axillary nodes i.e. the false-negative rate could not be 
determined. In 48 of these the SLN was negative and no axillary lymph 
node clearances were done. In the remaining 5, complete axillary lymph 
node clearances were done but there was no SLN biopsy in 2 as the SLN 
was in the IMN, and in 3 the SLN biopsies were cancelled due to theatre 
unavailability_ 
In this study we were able to identify the SLN in 99/103 procedures most of 
which were in the axilla 96/99. However, in 3199 procedures the SLNs were 
located only in the IMN. A SLN biopsy was not done in these 3 who went 
on to have a complete axillary lymph node clearance. 
Currently, there is no reliable data on local axillary recurrence and survival 
rates in patients who have had a node negative SLN biopsy_ 
The American College of Surgeons Oncology group, Z0011 35,97, the 
National Surgical Adjuvant Breast Project, B_3235,97, 127, 131 and the Almanac 
study132 are currently collating data on regional recurrence and survival of 




The SLN concept is established and will play an increasingly important role 
in the staging and management of the axilla in early breast carcinoma. 
An initial study consisting of both SLN biopsy and complete axillary 
dissection should be performed. Once the nuclear medicine physician and 
surgeon are sufficiently experienced and the identification and false-
negative rates of the SLN are acceptable, the technique can be adopted 
and complete axillary dissection can be abandoned in SLN negative 
patients. This technique also results in less radical surgery with a decrease 
in morbidity. 
Close communication and co-operation between nuclear medicine 
physician, surgeon and pathologist is essential for the successful 
implementation of the SLN technique. 
The single intratumoral injection technique with preoperative 
Iymphoscintigraphy has been shown in our study to be a valid and reliable 
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